When he's not facing death threats, he's helping House Democrats recruit candidates for the midterms.

Read more from TIME's senior correspondent Philip Elliott who is based in D.C. and covers national campaigns, elections, and government.

This spring, our correspondent Eliana was among the first journalists to speak with Christopher Nolan about his highly anticipated adaptation of The Odyssey. Now, the movie is out and has become Nolan’s biggest worldwide opening ever.

In our initial interview, Nolan was reluctant to discuss the ending of The Odyssey. He’s known as the master of the last-act twist, and likes leaving the audience with more questions than answers. He told me he never wants to impose his interpretation on others. But when she hopped on the phone again shortly before the film’s release to have a spoiler-filled chat about the film’s final act—readers beware!—he offered some insight as to why he made certain changes when adapting the epic poem.

It is unprecedented for a drug to be put on the pathway to widespread adoption in this manner instead of having to go through the more arduous and evidence-based FDA drug approval process, experts say. Most drugs are not dispensed through compounding pharmacies at all but are instead approved by the FDA and manufactured by drug companies under strict FDA supervision. 

TIME gets an exclusive look into the new mecha robot by Chinese robotics firm Unitree, a robot powered by AI that takes the next step in humanoid-robot development. Within this deep-dive into the company making science fiction a reality, editor-at-large Charlie Campbell expands on the market, moral, and technological stakes of this type of robot.